Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Investing.com - Mizuho has reiterated its Neutral rating and $24.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD), currently trading at $21.54, ahead of the company’s third-quarter 2025 earnings report. According to InvestingPro data, the stock has shown strong momentum with a 53% gain over the past six months, despite recent market volatility.
Mizuho raised its Q3 2025 total revenue forecast for Acadia from approximately $273 million to $277 million, aligning with consensus estimates. The adjustment reflects an increase in projected Nuplazid sales to match the consensus expectation of $174 million.
The firm maintained its Daybue sales forecast at $103 million, which is in line with consensus estimates. Mizuho’s Q3 2025 earnings per share forecast remains unchanged at $0.14, matching consensus expectations.
Mizuho noted that investors are likely to focus more on Acadia’s topline performance, particularly Daybue sales, rather than bottom-line results. The firm indicated that Acadia might narrow its 2025 sales guidance ranges for both Nuplazid and Daybue in the upcoming report.
Historically, Acadia has adjusted guidance during third-quarter reports by raising the low end of its range, though Mizuho does not anticipate significant changes to the overall guidance range.
In other recent news, Acadia Pharmaceuticals announced that its ACP-101 drug candidate failed to meet the primary endpoint in a Phase 3 clinical trial for Prader-Willi syndrome. This development led several analyst firms to adjust their price targets for the company. BMO Capital maintained its Outperform rating with a $28 price target, despite the trial miss. TD Cowen lowered its price target to $35 from $39, while still maintaining a Buy rating. Oppenheimer also reduced its price target to $21 from $22, keeping a Perform rating. In addition to these developments, Acadia Pharmaceuticals will present updates on its pipeline at the International Congress of Parkinson’s Disease and Movement Disorders. The company plans to showcase findings on ACP-711 and ACP-204, as well as a post-hoc analysis of NUPLAZID in Parkinson’s disease psychosis. These presentations are part of Acadia’s ongoing efforts to advance its research and development initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.